Aducanumab is an investigational human monoclonal antibody designed for the treatment of Alzheimer’s disease. It is designed to target and clear out amyloid-beta plaques, which are a major component of the disease. Aducanumab is being developed by Biogen and Eisai, and is currently in Phase 3 clinical trials. If approved, it would be the first therapy to target the underlying biology of Alzheimer’s disease.
Anatomical Therapeutic Chemical Classification
N - Nervous system
N06 Psychoanaleptics
N06D - Anti-dementia drugs
N06DX Other anti-dementia drugs
ATC Code
External Links
Aducanumab